Staphylococcal toxic shock syndrome: still a problem.
MacIsaac
Christopher M
CM
Page
Mark A
MA
Biggs
Beverley-Ann
BA
Visvanathan
Kumar
K
D000293:Adolescent; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000009:adverse effects; D004768:Enterotoxins / Q000009:adverse effects; D005260:Female; D006801:Humans; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis; D012772:Shock, Septic / Q000175:diagnosis* / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000175:diagnosis* / Q000188:drug therapy; D013211:Staphylococcus aureus; D018089:Superantigens / Q000009:adverse effects; D013601:T-Lymphocytes / Q000276:immunology; D013630:Tampons, Surgical / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D004768:Enterotoxins; D016693:Receptors, Antigen, T-Cell, alpha-beta; D018089:Superantigens; C030107:enterotoxin F, Staphylococcal; D019980:Amoxicillin-Potassium Clavulanate Combination